Gerard Plans

Gerard Plans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gerard Plans has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Jordi Bruna

    Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO l'Hospitalet, IDIBELL (Oncobell Program), Barcelona, Spain

    5 shared publications
  • Albert Pons-Escoda

    Radiology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Institut de Diagnòstic Per La Imatge (IDI), L'Hospitalet de Llobregat, Centre Bellvige, Barcelona, Spain; NeuroOncology Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain

    4 shared publications
  • Carles Majós

    Neuro-Oncology Unit, Bellvitge University Hospital-Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL); L'Hospitalet, Barcelona, Spain

    4 shared publications
  • Montserrat Alemany

    Cell Death, Senescence and Survival Group, Departament de Bioquímica i Biologia Molecular and Institut de Neurociències, Facultat de Medicina, Universitat Autònoma de Barcelona, Campus de Bellaterra , Bellaterra

    3 shared publications
  • Noemí Vidal

    NeuroOncology Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Pathology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

    3 shared publications
  • Aleix Rosselló

    Department of Neurosurgery, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, 08907 Barcelona, Spain

    2 shared publications

Latest Publications

  • Open Access

    Motor Deficits After Insular Glioma Surgery: Association with Postoperative Ischemia and Intraoperative Neuromonitoring

    by Gerard Plans, Isabel Fernández-Conejero, Daniel Martí, Pere J. Cifre-Serra, Albert Pons-Escoda, Alejandro Fernández-Coello, Júlia Miró, Aleix Rosselló, Andreu Gabarrós

    Background and Objectives: The proximity of insular gliomas to eloquent brain structures and complex vascular anatomy makes preservation of neurological function during resection challenging. This study investigates postoperative motor deficits after insular glioma resection and their association with intraoperative neuromonitoring and ischemia. Methods: In total, 64 patients who underwent insular glioma resection between 2018 and 2025 were included. Extent of resection (EOR), intraoperative MEP changes, subcortical stimulation thresholds, postoperative ischemic lesions and motor outcomes at 3 months were evaluated. Results: Median EOR was 93.4% (IQR 87.4–100%), and median residual tumor volume was 4.5 cm3 (IQR 0–8.1). MEP monitoring was performed in 56 patients (87.5%); deterioration occurred in 3 (5.4%), all of whom developed persistent deficits. MEP deterioration showed 60% sensitivity (95% CI 14.7–94.7%), 100% specificity (95% CI 93.0–100%), 100% positive predictive value (95% CI 29.2–100%), and 96.2% negative predictive value (95% CI 87.0–99.5%). The positive predictive value should be interpreted cautiously given the small number of events. Subcortical responses were elicited in 48 patients (85.7%). Tumors involving Berger–Sanai zones II and/or III had lower subcortical stimulation thresholds than tumors sparing both regions (median 4 vs. 8.5 mA; p = 0.012), although thresholds were not associated with motor deficits or ischemia. Postoperative ischemic lesions occurred in 20 patients (31.3%). Persistent motor deficits occurred in 6 patients (9.4%), all with associated ischemic lesions. Conclusions: Postoperative motor deficits were associated with ischemic lesions. MEP deterioration showed high specificity and positive predictive value, but limited sensitivity. Subcortical stimulation provided functional information about corticospinal tract proximity. These findings highlight the importance of preserving vascular supply to motor pathways during insular glioma surgery.

  • Salvage reirradiation for recurrent glioblastoma: a retrospective case series analysis

    by Anna Lucas Calduch, Miquel Macià Garau, Salvador Villà Freixa, Nagore García Expósito, Ignasi Modolell Farré, Carles Majós Torró, Albert Pons Escoda, Carlos Mesía Barroso, Noelia Vilariño Quintela, Aleix Rosselló Gómez, et al.

    Purpose To assess the clinical outcome of patients with recurrent glioblastoma treated with salvage reirradiation. Methods Between 2005 and 2022, data from adult patients with glioblastoma treated with surgery and radio-chemotherapy Stupp regimen who developed a local in-field relapse and received stereotactic radiotherapy (SRT) were retrospectively reviewed. Results The study population included 44 patients with recurrent glioblastoma (median of 9.5 months after the first radiotherapy). Reirradiation alone was given to 47.7% of patients. The median maximum diameter of the recurrence was 13.5 mm. The most common SRT regimen (52.3%) was 35 Gy in 10 fractions. Acute toxicity was mild, with transient worsening of previous neurological symptoms in only 15% of patients. After a median follow-up of 15 months, 40% presented radiological response, but a remarkable number of early distant progressions were recorded (32.5%). The median time to progression was 4.8 months, being the dose, the scheme, the size of the recurrence or the strategy (exclusive RT vs. combined) unrelated factors. The median overall survival (OS) was 14.9 months. Karnofsky index < 70 and the size of the recurrence (maximum diameter < 25 mm) were significant factors associated with OS. Radiological changes after reirradiation were commonly seen (> 50% of patients) hindering the response assessment. Conclusions Reirradiation is a feasible and safe therapeutic option to treat localized glioblastoma recurrences, able to control the disease for a few months in selected patients, especially those with good functional status and small lesions. Hypofractionated schemes provided a suitable toxicity profile. Radiological changes were common.


  • Open Access

    Normal Pressure Hydrocephalus Following Cranial Radiation: Identification of Shunting Responders

    by Nuria Cayuela, Manuel Domínguez-Lizarbe, Gerard Plans, Montserrat Alemany, Juan José Sánchez, Begoña Andrés, Anna Lucas, Jordi Bruna, Marta Simó

    Background: We examined cognitive, brain MRI, and lumbar infusion test (LIT) features to identify predictors of response to ventriculoperitoneal shunting (VPS) in long-term cancer survivors with suspected normal pressure hydrocephalus (NPH) following cranial radiotherapy (RT). Methods: Patients who completed cranial RT at least 2 years before with clinically suspected NPH and an Evans’ index (EI) ≥ 0.30 underwent a cognitive and a cerebrospinal fluid (CSF) volumetric (MRI) analysis (n = 36). For those in whom VPS was placed (n = 14), we explored whether adding a CSF volumetric analysis to classical MRI and LIT (Tap Test) features would better identify VPS responders. Results: Nearly 80% exhibited cognitive impairment. The CSF volume at NPH diagnoses was significantly larger in the group of VPS responders (p = 0.04). The addition of CSF volume to NPH diagnoses increased accuracy to 93%, with a positive and negative predictive value of 91% and 100%, respectively. Conclusion: The addition of a quantitative MRI analysis of CSF volume to classical MRI and LIT NPH criteria, along with a high clinical suspicion of NPH, may help to identify VPS responders, thus improving the clinical management and prognosis of long-term survivors.


  • Diffuse Large B-Cell Epstein-Barr Virus–Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics

    by A. Pons-Escoda, A. García-Ruíz, P. Naval-Baudin, F. Grussu, M. Viveros, N. Vidal, J. Bruna, G. Plans, M. Cos, R. Perez-Lopez, et al.

    BACKGROUND AND PURPOSE: Immunodeficiency-associated CNS lymphoma may occur in different clinical scenarios beyond AIDS. This subtype of CNS lymphoma is diffuse large B-cell and Epstein-Barr virus–positive. Its accurate presurgical diagnosis is often unfeasible because it appears as ring-enhancing lesions mimicking glioblastoma or metastasis. In this article, we describe clinicoradiologic features and test the performance of DSC-PWI metrics for presurgical identification. MATERIALS AND METHODS: Patients without AIDS with histologically confirmed diffuse large B-cell Epstein-Barr virus–positive primary CNS lymphoma (December 2010 to January 2022) and diagnostic MR imaging without onco-specific treatment were retrospectively studied. Clinical, demographic, and conventional imaging data were reviewed. Previously published DSC-PWI time-intensity curve analysis methodology, to presurgically identify primary CNS lymphoma, was used in this particular lymphoma subtype and compared with a prior cohort of 33 patients with Epstein-Barr virus–negative CNS lymphoma, 35 with glioblastoma, and 36 with metastasis data. Normalized curves were analyzed and compared on a point-by-point basis, and previously published classifiers were tested. The standard percentage of signal recovery and CBV values were also evaluated. RESULTS: Seven patients with Epstein-Barr virus–positive primary CNS lymphoma were included in the study. DSC-PWI normalized time-intensity curve analysis performed the best for presurgical identification of Epstein-Barr virus–positive CNS lymphoma (area under the receiver operating characteristic curve of 0.984 for glioblastoma and 0.898 for metastasis), followed by the percentage of signal recovery (0.833 and 0.873) and CBV (0.855 and 0.687). CONCLUSIONS: When a necrotic tumor is found in a potentially immunocompromised host, neuroradiologists should consider Epstein-Barr virus–positive CNS lymphoma. DSC-PWI could be very useful for presurgical characterization, with especially strong performance of normalized time-intensity curves.


  • Open Access

    Gossypol Treatment Restores Insufficient Apoptotic Function of DFF40/CAD in Human Glioblastoma Cells

    by Laura Martínez-Escardó, Montse Alemany, María Sánchez-Osuna, Alejandro Sánchez-Chardi, Meritxell Roig-Martínez, Salvio Suárez-García, Daniel Ruiz-Molina, Noemi Vidal, Gerard Plans, Carles Majós, et al.

    Glioblastoma (GBM) is a highly aggressive brain tumor and almost all patients die because of relapses. GBM-derived cells undergo cell death without nuclear fragmentation upon treatment with different apoptotic agents. Nuclear dismantling determines the point-of-no-return in the apoptotic process. DFF40/CAD is the main endonuclease implicated in apoptotic nuclear disassembly. To be properly activated, DFF40/CAD should reside in the cytosol. However, the endonuclease is poorly expressed in the cytosol and remains cumulated in the nucleus of GBM cells. Here, by employing commercial and non-commercial patient-derived GBM cells, we demonstrate that the natural terpenoid aldehyde gossypol prompts DFF40/CAD-dependent nuclear fragmentation. A comparative analysis between gossypol- and staurosporine-treated cells evidenced that levels of neither caspase activation nor DNA damage were correlated with the ability of each compound to induce nuclear fragmentation. Deconvoluted confocal images revealed that DFF40/CAD was almost completely excluded from the nucleus early after the staurosporine challenge. However, gossypol-treated cells maintained DFF40/CAD in the nucleus for longer times, shaping a ribbon-like structure piercing the nuclear fragments and building a network of bridged masses of compacted chromatin. Therefore, GBM cells can fragment their nuclei if treated with the adequate insult, making the cell death process irreversible.


  • Open Access

    Vagus nerve stimulation as a potential modulator of periictal psychotic episodes: A report of four cases

    by Montse Alemany, Eva Real, Núria Custal, Jacint Sala-Padró, Laura Rodríguez-Bel, Gerard Plans, Jaume Mora, Mila Santurino, Tim Vancamp, Mercè Falip


  • Presurgical Identification of Primary Central Nervous System Lymphoma with Normalized Time-Intensity Curve: A Pilot Study of a New Method to Analyze DSC-PWI

    by A. Pons-Escoda, A. Garcia-Ruiz, P. Naval-Baudin, M. Cos, N. Vidal, G. Plans, J. Bruna, R. Perez-Lopez, C. Majos

    BACKGROUND AND PURPOSE: DSC-PWI has demonstrated promising results in the presurgical diagnosis of brain tumors. While most studies analyze specific parameters derived from time-intensity curves, very few have directly analyzed the whole curves. The aims of this study were the following: 1) to design a new method of postprocessing time-intensity curves, which renders normalized curves, and 2) to test its feasibility and performance on the diagnosis of primary central nervous system lymphoma. MATERIALS AND METHODS: Diagnostic MR imaging of patients with histologically confirmed primary central nervous system lymphoma were retrospectively reviewed. Correlative cases of glioblastoma, anaplastic astrocytoma, metastasis, and meningioma, matched by date and number, were retrieved for comparison. Time-intensity curves of enhancing tumor and normal-appearing white matter were obtained for each case. Enhancing tumor curves were normalized relative to normal-appearing white matter. We performed pair-wise comparisons for primary central nervous system lymphoma against the other tumor type. The best discriminatory time points of the curves were obtained through a stepwise selection. Logistic binary regression was applied to obtain prediction models. The generated algorithms were applied in a test subset. RESULTS: A total of 233 patients were included in the study: 47 primary central nervous system lymphomas, 48 glioblastomas, 39 anaplastic astrocytomas, 49 metastases, and 50 meningiomas. The classifiers satisfactorily performed all bilateral comparisons in the test subset (primary central nervous system lymphoma versus glioblastoma, area under the curve = 0.96 and accuracy = 93%; versus anaplastic astrocytoma, 0.83 and 71%; versus metastases, 0.95 and 93%; versus meningioma, 0.93 and 96%). CONCLUSIONS: The proposed method for DSC-PWI time-intensity curve normalization renders comparable curves beyond technical and patient variability. Normalized time-intensity curves performed satisfactorily for the presurgical identification of primary central nervous system lymphoma.


  • Open Access

    Removing and reimplanting deep brain stimulation therapy devices in resistant OCD (when the patient does not respond): case report

    by Eva Real, Gerard Plans, Pino Alonso, Marco A. Aparicio, Cinto Segalàs, Narcís Cardoner, Carles Soriano-Mas, Clara López-Solà, José M. Menchón

    Deep brain stimulation (DBS) is emerging as a promising tool in the treatment of refractory obsessive-compulsive disorder (OCD) but the search for the best target still continues. This issue is especially relevant when particularly resistant profiles are observed in some patients, which have been ascribed to individual responses to DBS according to differential patterns of connectivity. As patients have been implanted, new dilemmas have emerged, such as what to do when the patient does not respond to surgery. Here we describe a 22-year-old male with extremely severe OCD who did not respond to treatment with DBS in the nucleus accumbens, but who did respond after explanting and reimplanting leads targeting the ventral capsule-ventral striatum region. Information regarding the position of the electrodes for both surgeries is provided and possible brain structures affected during stimulation are reviewed. To our knowledge this case is the first in the literature reporting the removal and reimplantation of DBS leads for therapeutical benefits in a patient affected by a mental disorder. The capability for explantation and reimplantation of leads should be considered as part of the DBS therapy reversibility profile in resistant mental disorders, as it allows application in cases of non-response to the first surgery.